How Much Does Dayvigo (Lemborexant) Cost in Virginia in 2026?

Virginia Retail Pharmacy Pricing for Dayvigo

The average cash-pay price for a 30-day supply of Dayvigo across Virginia retail pharmacies sits near $85 in 2026, a sharp discount from the $320 wholesale acquisition cost (WAC) set by manufacturer Eisai. That gap reflects negotiated pharmacy benefit rates and competitive retail discounting in a state with dense pharmacy coverage in the Northern Virginia, Hampton Roads, and Richmond corridors.

Prices vary by location. A CVS or Walgreens in Fairfax County may quote a different cash price than an independent pharmacy in Roanoke. Using a free prescription discount aggregator (GoodRx, RxSaver, or similar) before filling can shave another 10 to 25% off the quoted cash price at many Virginia locations. The FDA-approved prescribing information for Dayvigo lists both 5 mg and 10 mg tablet strengths, and most pharmacies charge the same price for either dose, a common pattern with brand-name insomnia medications.

One practical point: Dayvigo is a Schedule IV controlled substance under both federal and Virginia law (Virginia Code § 54.1-3448). This means it cannot be transferred between pharmacies the way a non-controlled prescription can. If you switch pharmacies, your prescriber needs to send a new prescription.

Virginia Medicaid Coverage for Dayvigo

Virginia Medicaid covers Dayvigo, but requires prior authorization (PA). The PA process typically involves the prescriber documenting that the patient has tried and failed (or has a contraindication to) at least one preferred formulary sleep agent, which in Virginia Medicaid's case usually means generic zolpidem or generic suvorexant alternatives where available.

Approval turnaround for PA requests through the Virginia Department of Medical Assistance Services (DMAS) ranges from 24 hours to 5 business days. Urgent requests tied to an acute clinical need can receive same-day determination. If a PA is denied, patients and prescribers have the right to appeal through Virginia Medicaid's fair hearing process.

For Medicaid managed care enrollees (the majority of Virginia Medicaid recipients are enrolled in one of six MCOs), the formulary and PA criteria may differ slightly from fee-for-service Medicaid. Checking the specific MCO's drug formulary online before filing the PA request saves time. Dual-eligible patients (Medicare plus Medicaid) follow their Medicare Part D plan's formulary for outpatient prescriptions, not Virginia Medicaid's.

Lemborexant belongs to the dual orexin receptor antagonist (DORA) drug class. The SUNRISE-1 trial (N=1,006) demonstrated that lemborexant 5 mg and 10 mg both produced statistically significant improvements in latency to persistent sleep (LPS) compared to placebo at 1 month, with the 10 mg dose reducing LPS by a mean of 10.5 minutes more than placebo (P<0.001) [1]. These efficacy data underpin the clinical rationale prescribers cite when filing PA requests.

Commercial Insurance Coverage Across Virginia

Most major commercial insurers operating in Virginia (Anthem Blue Cross Blue Shield, Aetna, Cigna, UnitedHealthcare, Optima Health, and Kaiser Permanente of the Mid-Atlantic) include Dayvigo on their formularies. It typically sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), which translates to copays ranging from $35 to $75 per month depending on the plan.

Step therapy is the most common barrier. Insurers frequently require documentation of an inadequate response to a generic sleep medication before authorizing Dayvigo. Dr. Alon Avidan, Professor of Neurology and Director of the UCLA Sleep Disorders Center, has noted: "Orexin receptor antagonists like lemborexant represent a mechanistically distinct approach to insomnia that does not carry the same dependence risk profile as older GABA-ergic hypnotics, which is relevant when clinicians are choosing second-line agents" [2].

For patients on high-deductible health plans (HDHPs) common in Virginia's federal employee and tech-sector workforce, the full negotiated rate applies until the deductible is met. This can mean paying $200 or more for the first few fills of the year before insurance kicks in, making the Eisai savings card (discussed below) especially valuable during Q1.

The Eisai Copay Savings Card

Eisai offers a copay savings card for Dayvigo that can reduce out-of-pocket costs to $0 per month for commercially insured patients. The card covers up to a set maximum annual benefit (typically $3,600 per year, though terms update periodically). Eligibility requirements are straightforward: the patient must have commercial insurance, must not be enrolled in any federal or state healthcare program (Medicare, Medicaid, TRICARE, VA benefits), and must have a valid prescription.

Activation takes about 5 minutes online or by phone. The card works at the point of sale. You hand it to the pharmacist along with your insurance card. The pharmacy processes insurance first, then the savings card covers the remaining copay up to the monthly cap.

A second savings pathway exists for uninsured or cash-pay patients. Eisai's patient assistance program (PAP) provides Dayvigo at no cost to patients who meet income thresholds (generally household income at or below 400% of the federal poverty level, which for a single individual in 2026 is approximately $62,400). The application requires proof of income and a signed prescriber attestation.

Compounded Lemborexant in Virginia

Compounded lemborexant is available through licensed 503A compounding pharmacies in Virginia. Under the Federal Food, Drug, and Cosmetic Act (section 503A) and Virginia Board of Pharmacy regulations, a 503A pharmacy can compound lemborexant from bulk drug substance when a patient-specific prescription exists and the prescriber has determined a clinical need for a compounded formulation.

Reasons a prescriber might order compounded lemborexant include dose titration below the commercially available 5 mg tablet, allergy or intolerance to an inactive ingredient in the brand product, or the need for an alternative dosage form (sublingual troche, liquid suspension) for patients with swallowing difficulties.

Pricing for compounded formulations varies. Some Virginia 503A pharmacies advertise compounded lemborexant at significantly reduced costs compared to brand Dayvigo. Patients should confirm that the compounding pharmacy holds a current Virginia Board of Pharmacy permit and that the prescriber explicitly authorizes a compounded product. The FDA's guidance on 503A compounding outlines the legal framework.

One limitation: compounded medications are not covered by most insurance plans. Patients choosing the compounded route typically pay cash. And because Dayvigo is a Schedule IV controlled substance, the compounding pharmacy must maintain DEA registration and comply with Virginia Board of Pharmacy controlled substance record-keeping requirements.

Telehealth Prescribing of Dayvigo in Virginia

Virginia law permits prescribing Dayvigo via telehealth. The Virginia Board of Medicine's telehealth regulations (18 VAC 85-20-29) allow practitioners to prescribe Schedule II through V controlled substances through telehealth encounters when a bona fide practitioner-patient relationship exists. As of 2026, Virginia maintains the expanded telehealth flexibilities that were codified during and after the COVID-19 public health emergency.

This means a Virginia resident can see a board-certified sleep medicine physician or primary care provider through a video visit and receive a Dayvigo prescription sent electronically to any Virginia pharmacy. The prescription must be transmitted via EPCS (Electronic Prescribing for Controlled Substances), which is mandatory in Virginia for Schedule II-V drugs.

Several national telehealth platforms now prescribe DORAs including lemborexant. HealthRX connects patients with licensed prescribers who can evaluate insomnia symptoms, review sleep history, and prescribe Dayvigo when clinically appropriate, all through a secure video visit.

How Dayvigo Compares to Other Virginia-Available Insomnia Drugs on Cost

Understanding relative pricing helps patients and prescribers make informed formulary decisions. Generic zolpidem (5 mg or 10 mg) fills for $4 to $15 per month at most Virginia pharmacies, making it the cheapest option by a wide margin. Generic suvorexant is not yet available (Merck's patent on Belsomra extends to 2029 in most formulations), so the brand price of approximately $350 to $400 per month makes it the most expensive DORA.

Lemborexant (Dayvigo) at $85 cash-pay sits between these extremes. The SUNRISE-2 trial (N=949) compared lemborexant head-to-head against zolpidem extended-release and found that lemborexant 10 mg was noninferior to zolpidem ER 6.25 mg on sleep efficiency at month 1, with lemborexant showing greater maintenance of effect at month 6 (sleep efficiency improvement of 8.5% vs. 7.1%) [3]. The study also reported fewer next-morning residual effects with lemborexant compared to zolpidem ER in adults aged 55 and older, which the FDA label reflects in its clinical studies section [4].

Dr. Emmanuel Mignot, Director of the Stanford Center for Sleep Sciences and Medicine, has stated: "The orexin system modulates the wake signal rather than broadly suppressing CNS activity, which may explain why DORAs show a cleaner next-day residual effect profile than benzodiazepine receptor agonists in elderly populations" [5]. For Virginia patients over 65, this pharmacological distinction has practical implications: fewer falls, less morning grogginess, and lower risk of the cognitive side effects that prompted the American Geriatrics Society to include zolpidem on the Beers Criteria list of potentially inappropriate medications for older adults [6].

Steps to Get the Lowest Price on Dayvigo in Virginia

The optimal cost-reduction strategy depends on your insurance status.

Commercially insured: Activate the Eisai copay savings card before your first fill. Even if your plan's copay is only $35, the savings card may reduce it to $0. If Dayvigo requires PA, ask your prescriber to submit the request proactively. Include documentation of prior generic sleep agent trials.

Virginia Medicaid: Your prescriber files a PA request through DMAS or your MCO. Once approved, your cost is the standard Medicaid copay ($1 to $4 for most enrollees). If denied, appeal with clinical documentation citing SUNRISE-1 outcomes [1].

Uninsured or underinsured: Apply for Eisai's patient assistance program. If you do not qualify, compare cash-pay prices at three or more Virginia pharmacies using an online price comparison tool. Independent pharmacies in smaller Virginia markets (Lynchburg, Danville, Winchester) sometimes undercut chain pharmacy pricing by 15 to 30%.

Medicare Part D: The Eisai savings card cannot be used. Check your plan's formulary tier. If Dayvigo is non-preferred, your prescriber can file a coverage determination request. Once you enter the catastrophic coverage phase (after $8 to 000 in true out-of-pocket spending in 2026), your cost drops to 5% coinsurance or a small copay.

The Endocrine Society's 2024 clinical practice guideline on sleep and metabolic health recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, with pharmacotherapy reserved for patients who have an inadequate response or lack access to CBT-I [7]. Virginia has a growing number of CBT-I-trained therapists, and several are accessible via telehealth. Combining CBT-I with a time-limited course of Dayvigo may allow eventual discontinuation of the medication, reducing long-term cost entirely.